One insomnia treatment carries a strong recommendation. No sleeping pill does.

If you want to know what the evidence supports for chronic insomnia, the fastest route is to read the grading rather than the prose. Across the two American guidelines that cover the ground, multicomponent cognitive behavioural therapy for insomnia is the only treatment that carries a strong recommendation [s1] [s3]. Every drug assessed in the sleep-medicine guideline — the eight it suggests using and the six it suggests avoiding — was graded weak [s2].

That asymmetry is the answer to the question most people are actually asking, and it is almost invisible in the way insomnia treatment is usually discussed.

What "strong" means, and who said it

The American Academy of Sleep Medicine's 2021 guideline on behavioural and psychological treatments was built by a task force of experts in sleep medicine and sleep psychology, using GRADE methodology, weighing quality of evidence, the balance of clinically relevant benefits and harms, patient values and preferences, and resource use [s1]. It issued six recommendations, and only one of them is strong: clinicians should use multicomponent cognitive behavioural therapy for insomnia for chronic insomnia disorder in adults [s1]. Under the guideline's own definition, a strong recommendation is one that clinicians should follow under most circumstances [s1].

Everything else in that document is conditional — meaning the clinician has to bring judgment and the patient's preferences to bear [s1]. Multicomponent brief therapies: conditional [s1]. Stimulus control as a single-component therapy: conditional [s1]. Sleep restriction therapy as a single-component therapy: conditional [s1]. Relaxation therapy: conditional [s1]. And sleep hygiene as a single-component therapy carries a conditional recommendation against [s1].

The American College of Physicians reached the same headline position five years earlier, from an independent systematic review of randomised controlled trials published in English from 2004 through September 2015. Its first recommendation is that all adult patients receive CBT-I as the initial treatment for chronic insomnia disorder, graded a strong recommendation on moderate-quality evidence [s3].

Two guideline panels, two evidence reviews, two grading systems, one conclusion. That kind of convergence is uncommon in sleep medicine and it is the strongest thing in this article.

What "weak" means, and why every drug got it

The 2017 AASM pharmacologic guideline broke with previous meta-analyses by evaluating individual drugs rather than classes of drug [s2]. It suggests clinicians use suvorexant for sleep maintenance insomnia; eszopiclone, zolpidem and temazepam for both sleep onset and sleep maintenance insomnia; zaleplon and triazolam for sleep onset insomnia; ramelteon for sleep onset insomnia; and doxepin for sleep maintenance insomnia [s2]. It suggests clinicians not use trazodone, tiagabine, diphenhydramine, melatonin, tryptophan or valerian [s2].

All fourteen of those recommendations are weak [s2].

The guideline explains why in advance rather than in hindsight. Downgrading the quality of evidence for these treatments is predictable under GRADE, it says, because of the funding source for most pharmacological clinical trials and the attendant risk of publication bias, the relatively small number of eligible trials for each individual agent, and the heterogeneity observed in the data [s2]. It also warns against the obvious misreading: a weak recommendation reflects a lower degree of certainty about the appropriateness of the strategy for all patients, and should not be construed as an indication of ineffectiveness [s2]. GRADE strength refers to the strength of evidence in published data, not to the size of the effect in a particular patient [s2].

So "weak" here is a statement about the evidence base, not a verdict that the drugs do nothing.

The nuance the ACP added

The ACP guideline did not stop at recommending CBT-I first. Its second recommendation is that clinicians use a shared decision-making approach — including a discussion of the benefits, harms and costs of short-term use of medications — to decide whether to add pharmacological therapy in adults in whom CBT-I alone was unsuccessful [s3]. That recommendation is graded weak, on low-quality evidence [s3].

Read together, the two ACP recommendations describe a sequence rather than a competition. The strong recommendation is about what to try first. The weak one is about what to discuss if that does not work, and its weakness is a candid statement that the evidence for the add-on step is thinner than the evidence for the first step.

Why the practical experience does not match the evidence

None of this tells you what most people with insomnia actually receive, and the guidelines are about what should be offered rather than what is available. A strong recommendation for a multi-session structured therapy is a different kind of instruction from a prescription, and it places a supply requirement on a health system that a prescription pad does not.

That is the gap worth watching, and it is the reason the guideline grading is worth quoting directly. The evidence question and the access question have different answers, and confusing them produces the two most common wrong summaries of this literature: that sleeping pills are the standard treatment because they work best, or that therapy is a soft alternative to real medicine. Neither survives contact with the grading tables [s1] [s2] [s3].

What is settled and what is not

Settled: two independent panels put CBT-I first, and one of them attached moderate-quality evidence to that call [s1] [s3]. Also settled, in the narrow sense that the guideline says so plainly: the randomised evidence for individual insomnia drugs is small in volume, heterogeneous, and vulnerable to publication bias [s2].

Not settled: which patients do best on which single component of CBT-I, since stimulus control, sleep restriction and relaxation all carry conditional recommendations rather than strong ones [s1]; and whether adding a drug after CBT-I fails improves outcomes, which the ACP could grade only on low-quality evidence [s3].

This article describes guideline positions and the evidence behind them. It is not medical advice, and decisions about insomnia treatment belong with a reader and their clinician.

Sources

• Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine, 2020-11-09
• Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline — Journal of Clinical Sleep Medicine, 2017-02-15
• Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians — Annals of Internal Medicine, 2016-05-03